Precigen (NASDAQ:PGEN) Receives Market Outperform Rating from JMP Securities

Precigen (NASDAQ:PGEN)‘s stock had its “market outperform” rating restated by JMP Securities in a report issued on Tuesday,Benzinga reports. They currently have a $5.00 price objective on the biotechnology company’s stock. JMP Securities’ price objective would suggest a potential upside of 365.12% from the company’s previous close.

Separately, HC Wainwright restated a “buy” rating and set a $4.00 price target on shares of Precigen in a research report on Friday, November 15th. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Precigen presently has a consensus rating of “Hold” and a consensus target price of $6.33.

Precigen Stock Up 0.5 %

PGEN stock traded up $0.01 during trading on Tuesday, hitting $1.08. 91,590 shares of the company’s stock traded hands, compared to its average volume of 2,551,000. The stock has a fifty day moving average price of $0.90 and a two-hundred day moving average price of $1.08. The stock has a market capitalization of $314.83 million, a price-to-earnings ratio of -1.95 and a beta of 1.65. Precigen has a 52 week low of $0.65 and a 52 week high of $1.93.

Hedge Funds Weigh In On Precigen

Institutional investors and hedge funds have recently bought and sold shares of the stock. Traphagen Investment Advisors LLC bought a new position in Precigen in the 3rd quarter valued at about $29,000. Stifel Financial Corp grew its position in Precigen by 94.9% in the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 15,680 shares in the last quarter. SG Americas Securities LLC grew its position in Precigen by 44.2% in the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 13,823 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Precigen by 86.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 25,681 shares in the last quarter. Finally, AQR Capital Management LLC grew its position in Precigen by 56.7% in the 2nd quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock valued at $79,000 after buying an additional 18,097 shares in the last quarter. Institutional investors own 33.51% of the company’s stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.